| 翻訳と辞書 |
ranibizumab
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Its effectiveness is similar to that of bevacizumab. Its rates of side effects also appear similar.〔 However, ranibizumab typically costs $2,000 a dose, while the equivalent dose of bevacizumab typically costs $50.〔〔(Switch From Lucentis to Avastin Could Save Medicare $18B ), Diedtra Henderson, Medscape, June 17, 2014〕
Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis,〔(Lucentis Fact Sheet ). Genentech.〕 under the brand name Lucentis.
==Pharmacology==
Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A, a mechanism similar to Bevacizumab.〔(【引用サイトリンク】title=ranibizumab )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「ranibizumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|